ReviewJournal of thoracic disease2026
Thoracic electrical impedance tomography from technological promise to clinical reality: the Chinese experience.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic electrical impedance tomography (EIT) has emerged as a powerful, non-invasive, and radiation-free tool for real-time bedside monitoring of regional lung ventilation and perfusion. Its unique ability to visualize spatial and temporal heterogeneity has established clinical value across intensive care, perioperative management, and chronic respiratory disease settings. Despite decades of recognized potential, the global translation of EIT from laboratory research to routine clinical practice has faced significant challenges, including high device costs, lack of standardization and guidelines, workflow integration challenges, and insufficient evidence linking its use to clinical outcomes. China's experience over the past decade presents a compelling and instructive case of rapid adoption that contrasts sharply with the slower global pace. Unlike prior descriptive reviews that catalogued milestones achieved, this article provided an analytical framework that examined how and why this accelerated translation occurred in China. It first evaluated the specific clinical value driving adoption across diverse scenarios. It then identified the distinctive ecosystem that enabled this rapid translation. Several factors worked synergistically: rapid clinical validation was achieved through China's vast hospital network. Domestic industry innovation drove down device costs and improved portability. Chinese researchers provided proactive leadership in building national and international standards. Most importantly, strategic government support-including reimbursement policies-removed economic barriers to adoption. Transferable lessons from this model were discussed for overcoming implementation barriers and accelerating the adoption of innovative medical technologies globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.